148 related articles for article (PubMed ID: 24574357)
1. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.
Schenone AD; Luo J; Montgomery L; Morgensztern D; Adkins DR; Van Tine BA
Cancer Med; 2014 Jun; 3(3):603-12. PubMed ID: 24574357
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.
Petrioli R; Coratti A; Correale P; D'Aniello C; Grimaldi L; Tanzini G; Civitelli S; Marsili S; Messinese S; Marzocca G; Pirtoli L; Francini G
Am J Clin Oncol; 2002 Oct; 25(5):468-73. PubMed ID: 12393986
[TBL] [Abstract][Full Text] [Related]
4. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
5. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
Frustaci S; Gherlinzoni F; De Paoli A; Bonetti M; Azzarelli A; Comandone A; Olmi P; Buonadonna A; Pignatti G; Barbieri E; Apice G; Zmerly H; Serraino D; Picci P
J Clin Oncol; 2001 Mar; 19(5):1238-47. PubMed ID: 11230464
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
Tanaka K; Mizusawa J; Fukuda H; Araki N; Chuman H; Takahashi M; Ozaki T; Hiruma T; Tsuchiya H; Morioka H; Hatano H; Iwamoto Y
Jpn J Clin Oncol; 2015 Jun; 45(6):555-61. PubMed ID: 25838293
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
10. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Frustaci S; Mercuri M; Martin J; Lopez-Pousa A; Verderio P; Mariani L; Valagussa P; Miceli R; Stacchiotti S; Dei Tos AP; De Paoli A; Longhi A; Poveda A; Quagliuolo V; Comandone A; Casali PG; Picci P
J Clin Oncol; 2012 Mar; 30(8):850-6. PubMed ID: 22312103
[TBL] [Abstract][Full Text] [Related]
11. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Hua Q; Xu G; Zhao L; Zhang T
J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
Brunello A; Rizzato MD; Rastrelli M; Roma A; Maruzzo M; Basso U; Fiduccia P; Buzzaccarini MS; Scarzello G; Rossi CR; Zagonel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):679-85. PubMed ID: 26547435
[TBL] [Abstract][Full Text] [Related]
13. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
Pervaiz N; Colterjohn N; Farrokhyar F; Tozer R; Figueredo A; Ghert M
Cancer; 2008 Aug; 113(3):573-81. PubMed ID: 18521899
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience.
Papadimitriou CA; Zorzou MP; Markaki S; Rodolakis A; Voulgaris Z; Bozas G; Kastritis E; Bamias A; Gika D; Dimopoulos MA
Eur J Gynaecol Oncol; 2007; 28(2):109-16. PubMed ID: 17479671
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.
Eraslan E; Ilhan Gulesen A; Yildiz F; Tufan G; Yalcintas Arslan U; Alkis N
J BUON; 2021; 26(5):2169-2175. PubMed ID: 34761631
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemotherapy of soft tissue sarcoma].
Lévy E; Thirion P; Piedbois P
Cancer Radiother; 1997; 1(5):462-6. PubMed ID: 9587378
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
Gortzak E; Azzarelli A; Buesa J; Bramwell VH; van Coevorden F; van Geel AN; Ezzat A; Santoro A; Oosterhuis JW; van Glabbeke M; Kirkpatrick A; Verweij J;
Eur J Cancer; 2001 Jun; 37(9):1096-103. PubMed ID: 11378339
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
20. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
MacDermed DM; Miller LL; Peabody TD; Simon MA; Luu HH; Haydon RC; Montag AG; Undevia SD; Connell PP
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1147-53. PubMed ID: 19577863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
